Swedish Orphan Biovitrum AB (Sobi) develops innovative therapies and services for the treatment of rare diseases. It develops, manufactures, and commercializes specialist pharmaceuticals and protein-based medicines. It offers pharmaceutical products for the treatment of various diseases in the areas of hematology, inflammation, autoimmune, inherited metabolic diseases, and cancer, among others. The company classifies its operations into three reportable segments: Haematology, Immunology, and Specialty Care.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Sob is focused on expanding existing products into new indications and regions, and gathering real-world evidence for available products. The company's research and development (R&D) is concentrated on late-stage research in the areas of Haematology and Immunology, where its pre-market assets hold considerable value. Sobi sees innovation as essential to its vision of being a global leader in rare diseases and continues providing innovative treatments, creating new evidence, and expanding the use of its medicines. At year-end, Sobi's main pipeline consisted of nine projects from Phase 2 through registration. In FY2025, the company spent SEK3,235 million on R&D, which, as a percentage of revenue, stood at 11.5% and declined 7.6% YoY. Some of its pipeline products in Phase III include Zynlonta (loncastuximab tesirine) to treat DLBCL, Diffuse large B-cell lymphoma (confirmatory & extension into second line or earlier in combination); Vonjo (pacritinib) to treat Myelofibrosis with severe thrombocytopenia; and Kineret (anakinra) to treat Still’s disease. Pipeline products in phase II include Vonjo (pacritinib) to treat Chronic myelomonocytic leukemia (CMML) and VEXAS (Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic), and Gamifant (emapalumab) to treat Cytokine release syndrome (CRS) prophylaxis in CAR-T therapy and Interferon-gamma-driven sepsis – IDS.